Babitt JL - Search Results

1

Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference.

Babitt JL, Eisenga MF, Haase VH, Kshirsagar AV, Levin A, Locatelli F, Małyszko J, Swinkels DW, Tarng DC, Cheung M, Jadoul M, Winkelmayer WC, Drüeke TB; Conference Participants. Babitt JL, et al. Kidney Int. 2021 Jun;99(6):1280-1295. doi: 10.1016/j.kint.2021.03.020. Epub 2021 Apr 8. Kidney Int. 2021. PMID: 33839163 Free article.

2

Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD.

Babitt JL, Lin HY. Babitt JL, et al. Am J Kidney Dis. 2010 Apr;55(4):726-41. doi: 10.1053/j.ajkd.2009.12.030. Epub 2010 Feb 26. Am J Kidney Dis. 2010. PMID: 20189278 Free PMC article. Review.

3

Mechanisms of anemia in CKD.

Babitt JL, Lin HY. Babitt JL, et al. J Am Soc Nephrol. 2012 Oct;23(10):1631-4. doi: 10.1681/ASN.2011111078. Epub 2012 Aug 30. J Am Soc Nephrol. 2012. PMID: 22935483 Free PMC article. Review.

4

Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production.

David V, Martin A, Isakova T, Spaulding C, Qi L, Ramirez V, Zumbrennen-Bullough KB, Sun CC, Lin HY, Babitt JL, Wolf M. David V, et al. Among authors: babitt jl. Kidney Int. 2016 Jan;89(1):135-46. doi: 10.1038/ki.2015.290. Epub 2016 Jan 4. Kidney Int. 2016. PMID: 26535997 Free PMC article.

5

Overview of iron metabolism in health and disease.

Dev S, Babitt JL. Dev S, et al. Among authors: babitt jl. Hemodial Int. 2017 Jun;21 Suppl 1(Suppl 1):S6-S20. doi: 10.1111/hdi.12542. Epub 2017 Mar 15. Hemodial Int. 2017. PMID: 28296010 Free PMC article. Review.

6

Iron, Hepcidin, and Death in Human AKI.

Leaf DE, Rajapurkar M, Lele SS, Mukhopadhyay B, Boerger EAS, Mc Causland FR, Eisenga MF, Singh K, Babitt JL, Kellum JA, Palevsky PM, Christov M, Waikar SS. Leaf DE, et al. Among authors: babitt jl. J Am Soc Nephrol. 2019 Mar;30(3):493-504. doi: 10.1681/ASN.2018100979. Epub 2019 Feb 8. J Am Soc Nephrol. 2019. PMID: 30737269 Free PMC article.

7

Crosstalk between fibroblast growth factor 23, iron, erythropoietin, and inflammation in kidney disease.

Babitt JL, Sitara D. Babitt JL, et al. Curr Opin Nephrol Hypertens. 2019 Jul;28(4):304-310. doi: 10.1097/MNH.0000000000000514. Curr Opin Nephrol Hypertens. 2019. PMID: 31145704 Free PMC article. Review.

8

Lipocalin 2 stimulates bone fibroblast growth factor 23 production in chronic kidney disease.

Courbon G, Francis C, Gerber C, Neuburg S, Wang X, Lynch E, Isakova T, Babitt JL, Wolf M, Martin A, David V. Courbon G, et al. Among authors: babitt jl. Bone Res. 2021 Aug 2;9(1):35. doi: 10.1038/s41413-021-00154-0. Bone Res. 2021. PMID: 34334787 Free PMC article.

9

Pumping iron in the kidney.

Fisher AL, Babitt JL. Fisher AL, et al. Among authors: babitt jl. Kidney Int. 2021 Sep;100(3):505-508. doi: 10.1016/j.kint.2021.06.023. Kidney Int. 2021. PMID: 34420657

10

Hyperphosphatemia increases inflammation to exacerbate anemia and skeletal muscle wasting independently of FGF23-FGFR4 signaling.

Czaya B, Heitman K, Campos I, Yanucil C, Kentrup D, Westbrook D, Gutierrez O, Babitt JL, Jung G, Salusky IB, Hanudel M, Faul C. Czaya B, et al. Among authors: babitt jl. Elife. 2022 Mar 18;11:e74782. doi: 10.7554/eLife.74782. Elife. 2022. PMID: 35302487 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

81 results

Search Page